-
Type 1 diabetes is associated with an increased risk of mortality, secondary to microvascular (neuropathy, nephropathy) and macrovascular (coronary artery disease, stroke, peripheral vascular disease) complications.
-
-
Bioprosthetic aorta valves are recommended for those > 70 years of age because of their reduced durability compared to mechanical valves and mechanical prostheses, which are recommended for those < 60 years because bioprosthetic valves deteriorate more rapidly in younger individuals.
-
Due to the short half-life and rapid onset of action of the new oral anticoagulants (NOACs), peri-procedural anticoagulant free time intervals should be shorter than with warfarin. Thus, there is uncertainty about the use of heparin bridging.
-
Although not a life-threatening condition, benign prostatic hypertrophy (BPH) is one of the most annoying and troublesome problems that plagues aging males.
-
Because of its strong efficacy, long-term durability, and predictability when titrated with algorithms employed in clinical trials, basal insulin remains a mainstay of treatment for type 2 diabetes patients who are not able to attain or maintain glycemic control with oral agents alone. Because diabetes is a progressive disorder, even patients who are initially well-controlled on basal insulin will likely require “fine tuning” of their diabetes regimen, usually with agents that preferentially affect postprandial glucose levels.
-
Hydrocodone is formulated to resist crushing, breaking, and dissolution and still retain some extended-release properties.
-
-
Terminally ill cancer patients who had end-of-life discussions with their physician had better quality of life during their last week, and their caregivers had an easier bereavement.
-
Unfractionated heparin (UFH) is the standard bridging therapy for patients with mechanical heart valves who need to temporarily stop oral anticoagulants. Small case series have suggested that low molecular weight heparin (LMWH) may be useful for this purpose.